International Journal of Scientific Research in Engineering and Management (IJSREM)
Volume: 09 Issue: 06 | June - 2025 SJIF Rating: 8.586 ISSN: 2582-3930

Homocysteine Metabolism and Its Clinical Significance

Pratham Patel ,Smit Patel , Aneri Sheth

Abstract:

Homocysteine (Hcy), a sulfur-containing amino acid derived from methionine, plays a pivotal role in both health and disease. Elevated levels of homocysteine, known as hyperhomocysteinemia (HHcy), have been associated with numerous age-related and chronic conditions, including cardiovascular diseases, stroke, Alzheimer's disease, Parkinson's disease, osteoporosis, and renal failure. This review outlines the biosynthesis, metabolism, and pathological roles of homocysteine and its metabolites, particularly homocysteine thiolactone (HTL). It explores the molecular mechanisms by which HHcy contributes to endothelial dysfunction, oxidative stress, and inflammation. Additionally, the article evaluates key studies investigating therapeutic interventions such as B-vitamin supplementation and choline/betaine therapy, while highlighting inconsistencies in clinical outcomes. By analyzing a broad range of studies, this review underscores the complexity of HHcy's role in disease pathogenesis and emphasizes the need for individualized clinical strategies. Continued research is essential to determine whether HHcy is a causative factor or merely a biomarker and to establish optimal treatment protocols.

Introduction:

Homocysteine metabolism has been extensively studied since McCully's hypothesis in 1969 linking elevated Hcy to arteriosclerosis. Over the past five decades, the role of Hcy has expanded into multiple clinical domains, ranging from vascular diseases to neurodegeneration and metabolic syndromes. Despite compelling associative data, questions remain whether HHcy acts as a causative factor or a secondary epiphenomenon. Understanding Hcy metabolism is essential, not only due to its impact on methylation reactions and redox homeostasis but also because of the growing body of literature highlighting its modifiable nature through dietary and pharmacological interventions. This review provides a detailed overview of Hcy biosynthesis, metabolic routes, clinical implications, and therapeutic strategies. We begin with the biochemistry of Hcy, followed by its physiological and pathological roles, and conclude with a discussion on treatment modalities and future research opportunities.

Body:

Biochemical Pathways of Homocysteine Metabolism: Homocysteine is an intermediary metabolite in methionine metabolism. Its fate is dictated by two primary metabolic pathways:

Remethylation Pathway: Hcy is remethylated back to methionine via methionine synthase (MS), which requires vitamin B12 as a cofactor and 5-methyltetrahydrofolate (derived from folic acid) as the methyl donor. In hepatic tissues, betaine (trimethylglycine) serves as an alternative methyl donor via betaine-homocysteine methyltransferase (BHMT).

Transsulfuration Pathway: In this irreversible pathway, Hcy is condensed with serine by cystathionine beta-synthase (CBS, vitamin B6-dependent) to form cystathionine, which is subsequently converted to cysteine by cystathionine gamma-lyase (CGL or CSE). This pathway also produces alpha-ketobutyrate and ammonia.Disruptions in these pathways due to genetic mutations (e.g., MTHFR, CBS deficiency) or nutritional deficiencies can lead to HHcy.

Toxic Metabolites and Their Impacts: Homocysteine Thiolactone (HTL): Formed via methionyl-tRNA synthetase misactivation of Hcy. HTL is a reactive thioester that can homocysteinylate lysine residues in proteins, creating neo-antigens and triggering autoimmune responses. It contributes to protein misfolding, cellular toxicity, and endothelial injury.Hydrogen Sulfide (H2S): A gasotransmitter synthesized during transsulfuration. H2S exerts vasodilatory, anti-inflammatory, and cytoprotective effects. Impaired H2S production has been linked to ischemia-reperfusion injuries and hypertension.

Clinical Associations of Hyperhomocysteinemia: Cardiovascular Diseases: HHcy induces endothelial dysfunction by reducing nitric oxide (NO) bioavailability and increasing oxidative stress. Hcy elevates asymmetric dimethylarginine (ADMA), an eNOS inhibitor, further reducing NO synthesis. Elevated Hcy correlates with increased risk of coronary artery disease, carotid stenosis, and venous thrombosis.

Neurological Disorders: HHcy is linked with Alzheimer's and Parkinson's disease through mechanisms including beta-amyloid deposition, NMDA receptor excitation, and oxidative stress. Elevated plasma Hcy levels have also been associated with stroke risk and vascular dementia.

Osteoporosis: HHcy interferes with collagen cross-linking, promoting bone fragility. It increases osteoclast activity and reduces bone blood flow, contributing to decreased bone mineral density.

Renal Disease: In chronic kidney disease (CKD) and ESRD, reduced renal clearance of Hcy leads to systemic accumulation. Dialysis may transiently reduce Hcy but does not resolve HHcy.

Diabetes and Insulin Resistance: Hcy impairs insulin receptor signaling and GLUT4 translocation. It induces ER stress and elevates resistin expression, promoting insulin resistance.

Other Conditions: HHcy has been linked to abdominal aortic aneurysm, hypothyroidism, cancers (notably hepatocellular carcinoma via Cyp450 epigenetics), and gastrointestinal inflammatory conditions.

Estimation and Diagnostic Classification: Total homocysteine (tHcy) includes free, protein-bound, and disulfide forms. Normal levels range from 5–15 µmol/L. HHcy is classified as:

Mild: 15–30 µmol/L

Intermediate: 30–100 µmol/L

Severe: >100 µmol/L

Measurement techniques include HPLC with fluorescent detection, LC-MS/MS, and immunoassays.

Therapeutic Interventions and Challenges: Vitamin Therapy: Folic acid, vitamin B12, and B6 supplementation lowers plasma Hcy levels. However, large trials (HOPE-2, NORVIT, VISP) yielded inconclusive benefits on cardiovascular outcomes, possibly due to short durations and patient heterogeneity.

Alternative Therapies: Choline and betaine supplementation act via BHMT, independent of folate/B12 pathways. Antioxidants like N-acetyl cysteine (NAC) support glutathione production and reduce oxidative stress. Nebivolol, a β1-blocker with NO-enhancing properties, has shown Hcy-lowering potential in animal studies.

Drug-Induced HHcy: Medications such as phenytoin, valproic acid, L-DOPA, and fenofibrate increase Hcy levels by disrupting folate metabolism or methylation cycles.

Conclusions

HHcy is a critical biomarker with multifactorial implications in human disease. Although lowering Hcy via B-vitamin therapy is biochemically effective, its clinical efficacy remains controversial. The complexity of Hcy's interactions—ranging from gene-nutrient interplay to downstream effects like HTL formation and NO inhibition—necessitates more nuanced research. Future studies should focus on patient stratification, long-term interventions, and mechanistic explorations, particularly in genetically predisposed populations. Understanding whether HHcy is causative or correlative will guide preventive strategies and personalized treatments.

Literature Cited:

McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111-128.

Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369(9576):1876-1882.

Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346(7):476-483.

Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 1996;98(1):5-7.

Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989;114(5):473-501.

Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332(5):286-291.

Smulders YM, Blom HJ. The homocysteine controversy. J Inherit Metab Dis. 2011;34(1):93-99.

Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci. 2004;61(4):470-487.

Golbahar J, Aminzadeh MA, Kassab SE, Omrani GR. Hyperhomocysteinemia induces insulin resistance in male Sprague–Dawley rats. Diabetes Res Clin Pract. 2007;76(1):1-5.

Perna AF, Sepe I, Lanza D, et al. Hyperhomocysteinemia in chronic renal failure: alternative therapeutic strategies. J Ren Nutr. 2012;22(2):191-194.